

**Adult CIRB - Late Phase Emphasis Meeting Agenda**

**January 16, 2020**

---

---

**I Continuing Review**

**NRG-GI005**, Phase II/III Study of Circulating tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA) (Protocol Version Date 09/16/19)

---

---

**I New Study - Initial Review**

**EA5182**, Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) (Protocol Version Date 12/10/19)

---